Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GC Pharma Aiming To Outrun Rivals For COVID-19 Plasma Therapy

Korean Firm Plans Trial Start Soon

Executive Summary

A South Korean pharma firm is set to soon begin pivotal clinical trials for a hyperimmune globulin for the treatment of COVID-19 patients and plans to commercialize the product this year, with a hope of outrunning rivals including Takeda.

You may also be interested in...



Webinar Recording: Coronavirus Pharma Industry Impact In China, Korea And Japan

Join Jung Won Shin, Brian Yang and Ian Haydock in this recorded session from Informa Pharma Intelligence's recent 24-hour webinar series, COVID-19: Lessons Learned And A Path Forward.

GC Pharma Preps For Life After Sale Of North American Subsidiaries

South Korean firm outlines R&D milestones for this year including progress with a plasma therapy for COVID-19, as well as other challenges and opportunities amid the pandemic.

How Was Korea Different In Handling COVID-19 Situation?

South Korea authorities talk to foreign media about the country's experience and successes in dealing with the COVID-19 situation, lessons learned, preparations being made to return to everyday life and R&D activity.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142011

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel